From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs)

Suzanne E. Wardell, Erik R. Nelson, Donald P. McDonnell

Research output: Contribution to journalArticle

Abstract

Our understanding of the molecular mechanisms underlying the pharmacological actions of estrogen receptor (ER) ligands has evolved considerably in recent years. Much of this knowledge has come from a detailed dissection of the mechanism(s) of action of the Selective Estrogen Receptor Modulators (SERMs) tamoxifen and raloxifene, drugs whose estrogen receptor (ER) agonist/antagonist properties are influenced by the cell context in which they operate. These studies have revealed that notwithstanding differences in drug pharmacokinetics, the activity of an ER ligand is determined primarily by (a) the impact that a given ligand has on the receptor conformation and (b) the ability of structurally distinct ER-ligand complexes to interact with functionally distinct coregulators. Exploitation of the established relationships between ER structure and activity has led to the development of improved SERMs with more favorable therapeutic properties and of tissue-selective estrogen complexes, drugs in which a SERM and an ER agonist are combined to yield a blended activity that results in distinct clinical profiles. Remarkably, endogenous ligands that exhibit SERM activity have also been identified. One of these ligands, 27-hydroxycholesterol (27HC), has been shown to manifest ER-dependent pathological activities in the cardiovascular system, bone and mammary gland. Whereas the physiological activity of 27HC remains to be determined, its discovery highlights how cells have adopted mechanisms to allow the same receptor ligand complex to manifest different activities in different cells, and also how these processes can be exploited for new drug development.

Original languageEnglish (US)
Pages (from-to)30-38
Number of pages9
JournalSteroids
Volume90
DOIs
StatePublished - Nov 15 2014
Externally publishedYes

Fingerprint

Selective Estrogen Receptor Modulators
Ligands
Estrogen Receptors
Estrogens
Pharmaceutical Preparations
Molecular Mechanisms of Pharmacological Action
Cardiovascular system
Dissection
Pharmacokinetics
Tamoxifen
Human Mammary Glands
Cardiovascular System
Conformations
Bone
Tissue
Bone and Bones

Keywords

  • Estrogen receptor
  • SERM
  • Selective estrogen receptor modulator
  • TSEC
  • Tamoxifen

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Endocrinology
  • Pharmacology
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs). / Wardell, Suzanne E.; Nelson, Erik R.; McDonnell, Donald P.

In: Steroids, Vol. 90, 15.11.2014, p. 30-38.

Research output: Contribution to journalArticle

@article{462bb2def5d94721b59d88dda8ac809b,
title = "From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs)",
abstract = "Our understanding of the molecular mechanisms underlying the pharmacological actions of estrogen receptor (ER) ligands has evolved considerably in recent years. Much of this knowledge has come from a detailed dissection of the mechanism(s) of action of the Selective Estrogen Receptor Modulators (SERMs) tamoxifen and raloxifene, drugs whose estrogen receptor (ER) agonist/antagonist properties are influenced by the cell context in which they operate. These studies have revealed that notwithstanding differences in drug pharmacokinetics, the activity of an ER ligand is determined primarily by (a) the impact that a given ligand has on the receptor conformation and (b) the ability of structurally distinct ER-ligand complexes to interact with functionally distinct coregulators. Exploitation of the established relationships between ER structure and activity has led to the development of improved SERMs with more favorable therapeutic properties and of tissue-selective estrogen complexes, drugs in which a SERM and an ER agonist are combined to yield a blended activity that results in distinct clinical profiles. Remarkably, endogenous ligands that exhibit SERM activity have also been identified. One of these ligands, 27-hydroxycholesterol (27HC), has been shown to manifest ER-dependent pathological activities in the cardiovascular system, bone and mammary gland. Whereas the physiological activity of 27HC remains to be determined, its discovery highlights how cells have adopted mechanisms to allow the same receptor ligand complex to manifest different activities in different cells, and also how these processes can be exploited for new drug development.",
keywords = "Estrogen receptor, SERM, Selective estrogen receptor modulator, TSEC, Tamoxifen",
author = "Wardell, {Suzanne E.} and Nelson, {Erik R.} and McDonnell, {Donald P.}",
year = "2014",
month = "11",
day = "15",
doi = "10.1016/j.steroids.2014.07.013",
language = "English (US)",
volume = "90",
pages = "30--38",
journal = "Steroids",
issn = "0039-128X",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs)

AU - Wardell, Suzanne E.

AU - Nelson, Erik R.

AU - McDonnell, Donald P.

PY - 2014/11/15

Y1 - 2014/11/15

N2 - Our understanding of the molecular mechanisms underlying the pharmacological actions of estrogen receptor (ER) ligands has evolved considerably in recent years. Much of this knowledge has come from a detailed dissection of the mechanism(s) of action of the Selective Estrogen Receptor Modulators (SERMs) tamoxifen and raloxifene, drugs whose estrogen receptor (ER) agonist/antagonist properties are influenced by the cell context in which they operate. These studies have revealed that notwithstanding differences in drug pharmacokinetics, the activity of an ER ligand is determined primarily by (a) the impact that a given ligand has on the receptor conformation and (b) the ability of structurally distinct ER-ligand complexes to interact with functionally distinct coregulators. Exploitation of the established relationships between ER structure and activity has led to the development of improved SERMs with more favorable therapeutic properties and of tissue-selective estrogen complexes, drugs in which a SERM and an ER agonist are combined to yield a blended activity that results in distinct clinical profiles. Remarkably, endogenous ligands that exhibit SERM activity have also been identified. One of these ligands, 27-hydroxycholesterol (27HC), has been shown to manifest ER-dependent pathological activities in the cardiovascular system, bone and mammary gland. Whereas the physiological activity of 27HC remains to be determined, its discovery highlights how cells have adopted mechanisms to allow the same receptor ligand complex to manifest different activities in different cells, and also how these processes can be exploited for new drug development.

AB - Our understanding of the molecular mechanisms underlying the pharmacological actions of estrogen receptor (ER) ligands has evolved considerably in recent years. Much of this knowledge has come from a detailed dissection of the mechanism(s) of action of the Selective Estrogen Receptor Modulators (SERMs) tamoxifen and raloxifene, drugs whose estrogen receptor (ER) agonist/antagonist properties are influenced by the cell context in which they operate. These studies have revealed that notwithstanding differences in drug pharmacokinetics, the activity of an ER ligand is determined primarily by (a) the impact that a given ligand has on the receptor conformation and (b) the ability of structurally distinct ER-ligand complexes to interact with functionally distinct coregulators. Exploitation of the established relationships between ER structure and activity has led to the development of improved SERMs with more favorable therapeutic properties and of tissue-selective estrogen complexes, drugs in which a SERM and an ER agonist are combined to yield a blended activity that results in distinct clinical profiles. Remarkably, endogenous ligands that exhibit SERM activity have also been identified. One of these ligands, 27-hydroxycholesterol (27HC), has been shown to manifest ER-dependent pathological activities in the cardiovascular system, bone and mammary gland. Whereas the physiological activity of 27HC remains to be determined, its discovery highlights how cells have adopted mechanisms to allow the same receptor ligand complex to manifest different activities in different cells, and also how these processes can be exploited for new drug development.

KW - Estrogen receptor

KW - SERM

KW - Selective estrogen receptor modulator

KW - TSEC

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=84908668490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908668490&partnerID=8YFLogxK

U2 - 10.1016/j.steroids.2014.07.013

DO - 10.1016/j.steroids.2014.07.013

M3 - Article

C2 - 25084324

AN - SCOPUS:84908668490

VL - 90

SP - 30

EP - 38

JO - Steroids

JF - Steroids

SN - 0039-128X

ER -